Ainnocence, co-founded by a dynamic team of biomedical and AI scientists, offers groundbreaking AI-based systems for designing both small and large molecules. These systems significantly reduce the costs and risks associated with drug discovery, bringing the industry closer to solutions for some of humanity’s most challenging diseases.

“Our goal is to empower biotech and pharmaceutical companies to pursue ambitious ‘moonshot’ cures, previously deemed unfeasible due to exorbitant discovery costs and low success rates,” said Dr. Lurong Pan, Founder of Ainnocence and a veteran with 15 years in AI for drug discovery. “With our technology, drug discovery teams gain access to unprecedented capabilities. By simply providing the sequence of their biological targets, we can screen billions of protein molecules within hours. This efficiency often allows us to bypass extensive wet-lab experiments or certain animal studies, streamlining the entire discovery process.”